

**Evoke Pharma, Inc.**  
**420 Stevens Avenue, Suite 230**  
**Solana Beach, CA 92075**

September 4, 2024

**VIA EDGAR**

U.S. Securities and Exchange Commission  
Division of Corporation Finance  
100 F Street, N.E.  
Washington, D.C. 20549

**Re: Evoke Pharma, Inc.**  
**Registration Statement on Form S-3**

**File No. 333-281840**

To the addressees set forth above:

Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, on behalf of Evoke Pharma, Inc., respectfully requests that the effective date of the Registration Statement on Form S-3 referred to above be accelerated so that it will become effective at 4:00 P.M. Eastern Time on September 6, 2024, or as soon as practicable thereafter.

If you have any questions or require additional information, please contact Matthew T. Bush, Esq. of Latham & Watkins LLP at (858) 523-3962. Thank you for your assistance and cooperation in this matter.

Very truly yours,

EVOKE PHARMA, INC.

By: /s/ Matthew J. D'Onofrio  
Matthew J. D'Onofrio

Chief Executive Officer

cc: Mark Kowieski, Evoke Pharma, Inc.  
Cheston J. Larson, Latham & Watkins LLP  
Matthew T. Bush, Latham & Watkins LLP  
Anthony A. Gostanian, Latham & Watkins LLP

|||

---